MYNZ Mainz Biomed NV: ערך חשבונאי למניה

Steady demand for ColoAlert systems for early colorectal cancer detection provides Mainz Biomed N.V. (MYNZ) with a regular cash flow. The book value per share visualizes this foundation, linking revenues with high R&D costs and biomarker patenting. The current metric has settled at 0.32, confirming capital resilience despite dependence on insurance reimbursements and sales in the US and Europe.

Mainz Biomed N.V. (MYNZ) is scaling a high-margin cloud AI DNA diagnostics analysis model, where the primary test development costs have already been locked in. By analyzing the book value per share curve, an investor can see the remaining net assets after all liabilities are settled, which allows for tracking the impact of secondary offerings and confirming the fundamental stability of the company's assets relative to its market capitalization.